Market Access

China’s growing market for medtech, estimated at $70bn in 2021, could more than double this decade if the government’s Healthy China 2030 plan stays on track.  

Overcoming Inertia is a challenge. Physicians want novel and better medications and products, but evaluating and trying new products takes time and may involve risk. 

Harsh economic conditions and increased competition are dictating that surgical robotics companies must quickly adopt new commercial strategies. In Vivo speaks to key players in the space to learn more.

In an environment replete with pricing and patient access pressures, top biopharma companies are building commercialization models that emphasize inclusive and diverse decision-making and that integrate digital tools with a human salesforce.

Infex CEO Peter Jackson discusses the state of antimicrobial resistance in the UK, and globally. He highlights the potential of a new “Netflix” style subscription model for antibiotic reimbursement, as well as future challenges for biotechs in the anti-infectives space. 

After the historic approvals of Seres’ and Ferring’s microbiome-based treatments for recurrent Clostridioides difficile infection, the two companies are waiting to see who dominates the $1bn market. Physicians say patients will steer the choice of treatments.

With strong government support over the past two decades, the Singaporean life sciences industry has matured. Initially known as a manufacturing hub, Singapore’s innovation ecosystem is now thriving, but the challenge is to cultivate commercialization power.

As Boehringer Ingelheim launches the first – and so far, only – interchangeable US adalimumab biosimilar, the firm’s biosimilar commercial brand lead Stephen Pagnotta talks about how the interchangeability designation puts the firm in a unique position when it comes to competing with Humira.

A new report from legal and consultancy firm CMS shines a light on the healthcare industry’s adoption of emerging technology. Survey data reveal the aspirations and latent fears of healthcare innovators as they navigate through the maze of AI, IP and data. CMS partner Jeremy Mash explains the background.

Sales of a global first-in-class dermatology drug that gained its first approval in China are falling well behind those of its overseas counterpart. Brian Yang takes a deeper look into the multiple underlying factors determining success in the world's second-largest pharma market beyond pricing and reimbursement coverage, including complex hospital entry, dual channels and competition considerations. 

Market access deals can make or break routine access to new treatments. So what happens when patient-centricity and deal-making meet? Leela Barham looks at the experience in England.

Welcome to Inflection to Insight, a new series taking a closer look at notable chapters in biopharma history, gleaning learnings to inform current business strategy. This inaugural instalment looks at the rapid rise and fall of two competing drugs for hepatitis C virus, Vertex’s Incivek and Merck & Co’s Victrelis.

As the Kingdom of Saudi Arabia reduces its dependence on oil as an export, one sector it is building up is the life sciences industry. The government is encouraging global companies to manufacture and invest domestically and they are improving their regulatory system and working with local players to enhance access to patients.

Regulatory interventions are the preferred route for ensuring sustainability compliance, says the OECD. Legal firm CMS notes that some ESG objectives may be in contravention of antitrust law. The EU is preparing guidelines on horizontal competition with a renewed focus on sustainability.

New policy initiatives and “can do” networking openness in Wales are persuading medtech and healthtech innovators to consider the merits of locating in Great Britain’s smallest home nation.

Pfizer and GSK are expected to gain approval and launch in time for this year’s flu season, but must educate public and physicians